2.68
price up icon4.28%   0.11
after-market Handel nachbörslich: 2.75 0.07 +2.61%
loading
Schlusskurs vom Vortag:
$2.57
Offen:
$2.5
24-Stunden-Volumen:
16.63M
Relative Volume:
1.00
Marktkapitalisierung:
$894.94M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.6048
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
-14.38%
1M Leistung:
+54.02%
6M Leistung:
-54.19%
1J Leistung:
-67.16%
1-Tages-Spanne:
Value
$2.45
$2.71
1-Wochen-Bereich:
Value
$2.45
$3.41
52-Wochen-Spanne:
Value
$1.6385
$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Firmenname
Iovance Biotherapeutics Inc
Name
Telefon
(650) 260-7120
Name
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Mitarbeiter
838
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IOVA
Iovance Biotherapeutics Inc
2.68 858.21M 32.77M -440.22M -400.48M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.13 117.32B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.87 58.89B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
401.80 51.14B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
673.80 41.02B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.01 32.59B 3.81B -644.79M -669.77M -6.24

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-15 Herabstufung Goldman Neutral → Sell
2025-05-16 Herabstufung UBS Buy → Neutral
2025-05-12 Herabstufung Truist Buy → Hold
2025-05-09 Herabstufung Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 Eingeleitet UBS Buy
2024-07-29 Herabstufung Piper Sandler Overweight → Neutral
2023-11-20 Eingeleitet Goldman Buy
2023-09-18 Bestätigt Barclays Overweight
2023-05-30 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-27 Fortgesetzt Wells Fargo Equal Weight
2023-01-27 Hochstufung Piper Sandler Neutral → Overweight
2022-12-09 Herabstufung Goldman Buy → Neutral
2022-10-31 Eingeleitet Guggenheim Neutral
2022-08-18 Fortgesetzt Wells Fargo Equal Weight
2022-01-28 Hochstufung Stifel Hold → Buy
2021-12-07 Fortgesetzt Cowen Outperform
2021-06-10 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 Herabstufung Piper Sandler Overweight → Neutral
2021-05-19 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 Herabstufung Stifel Buy → Hold
2021-05-03 Eingeleitet Truist Buy
2021-04-16 Eingeleitet Goldman Buy
2021-03-08 Hochstufung H.C. Wainwright Neutral → Buy
2020-12-15 Herabstufung H.C. Wainwright Buy → Neutral
2020-10-06 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-22 Eingeleitet Mizuho Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-02-26 Bestätigt H.C. Wainwright Buy
2020-02-26 Bestätigt Oppenheimer Outperform
2019-12-18 Eingeleitet JMP Securities Mkt Outperform
2019-10-01 Eingeleitet Stifel Buy
2019-04-29 Eingeleitet Piper Jaffray Overweight
2019-02-28 Bestätigt Chardan Capital Markets Buy
2019-02-07 Eingeleitet Robert W. Baird Outperform
2018-12-31 Fortgesetzt B. Riley FBR Buy
2018-07-06 Bestätigt Chardan Capital Markets Buy
2018-04-10 Hochstufung B. Riley FBR, Inc. Neutral → Buy
2018-03-13 Bestätigt B. Riley FBR, Inc. Neutral
2018-02-23 Herabstufung B. Riley FBR, Inc. Buy → Neutral
2018-01-25 Bestätigt H.C. Wainwright Buy
2017-11-01 Bestätigt B. Riley FBR, Inc. Buy
Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

pulisher
Aug 03, 2025

Is Iovance Biotherapeutics Inc. stock overvalued or undervaluedMarket-leading growth rates - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

What are Iovance Biotherapeutics Inc. company’s key revenue driversMassive wealth growth - jammulinksnews.com

Aug 03, 2025
pulisher
Aug 03, 2025

Will Iovance Biotherapeutics Inc. price bounce be sustainableFree Early Entry Picks Before News Breakout - Newser

Aug 03, 2025
pulisher
Aug 02, 2025

What institutional investors are buying Iovance Biotherapeutics Inc. stockAchieve consistent profits with proven strategies - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

What are the latest earnings results for Iovance Biotherapeutics Inc.Invest smarter with actionable trading signals - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 01, 2025

What is the dividend policy of Iovance Biotherapeutics Inc. stockStock Market Picks With High Returns - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

A Closer Look at Iovance Biotherapeutics Inc (IOVA) Stock Gains - investchronicle.com

Aug 01, 2025
pulisher
Aug 01, 2025

Iovance Biotherapeutics: Unlocking TIL Therapy's Potential Amid Funding Challenges - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis

Aug 01, 2025
pulisher
Aug 01, 2025

Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Intraday pattern recognizer results for Iovance Biotherapeutics Inc.Real-Time Setup Summary with ROI Focus - Newser

Aug 01, 2025
pulisher
Jul 31, 2025

Iovance Biotherapeutics: Recent Clinical Study Results and Leadership Appointments Boost Growth Prospects - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Iovance Biotherapeutics shares rise 4.12% premarket after Eisai and Biogen's Alzheimer's drug LEQEMBI shows sustained long-term benefits. - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

Exit strategy if you’re trapped in Iovance Biotherapeutics Inc.Chart Driven Entry Timing for Swing Trades - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

What is the risk reward ratio of investing in Iovance Biotherapeutics Inc. stockEarnings Report Planner For 2025 - jammulinksnews.com

Jul 31, 2025
pulisher
Jul 31, 2025

Iovance Biotherapeutics Inc. Building a Base Near SupportSwing Trade Entry Alert Analysis - beatles.ru

Jul 31, 2025
pulisher
Jul 31, 2025

What moving averages say about Iovance Biotherapeutics Inc.Real Time Growth Signal with Smart Setup - Newser

Jul 31, 2025
pulisher
Jul 31, 2025

Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis

Jul 31, 2025
pulisher
Jul 30, 2025

Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com

Jul 30, 2025
pulisher
Jul 30, 2025

Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade

Jul 30, 2025
pulisher
Jul 30, 2025

Is Iovance Biotherapeutics Stock Due for a Big Rally? - Mitrade

Jul 30, 2025
pulisher
Jul 30, 2025

Using AI based signals to follow Iovance Biotherapeutics Inc.Chart Pattern Recognition for Profit Timing - Newser

Jul 30, 2025
pulisher
Jul 30, 2025

Can Iovance Biotherapeutics Inc. rally from current levelsShort-Term Profit Alert With Entry Forecast - newser.com

Jul 30, 2025
pulisher
Jul 30, 2025

How to monitor Iovance Biotherapeutics Inc. with trend dashboardsReliable Setup Screener with Low Risk - Newser

Jul 30, 2025
pulisher
Jul 29, 2025

Is Iovance Biotherapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Optimized Watchlist With Daily Adjustments - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 18:47:39 - beatles.ru

Jul 29, 2025
pulisher
Jul 29, 2025

Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionReal Time Trade Execution Alert Plan - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Iovance Biotherapeutics Inc. Company Revenue and Profit Trends: A Deep DiveWatchlist for Low Risk High Return Stocks Updated - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Price momentum metrics for Iovance Biotherapeutics Inc. explainedMomentum Prediction Based on AI Backtesting - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Iovance Biotherapeutics shares rise 2.03% premarket after UK's MHRA approves Tofersen for rare motor neurone disease. - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - Yahoo Finance

Jul 29, 2025
pulisher
Jul 28, 2025

Iovance Biotherapeutics’ SWOT analysis: stock faces challenges amid promising data - Investing.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Iovance Biotherapeutics Inc.Turbocharged investment results - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Does Iovance Biotherapeutics Inc. stock perform well during market downturnsRecord-breaking capital gains - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How Iovance Biotherapeutics Inc. stock performs during market volatilitySwing Entry Risk Mitigation with Chart Analysis - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

What are analysts’ price targets for Iovance Biotherapeutics Inc. in the next 12 monthsSkyrocketing profit margins - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Is Iovance Biotherapeutics Inc. Stock a Good Fit for Conservative InvestorsDaily Top Gainers - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank of New York Mellon Corp - Defense World

Jul 27, 2025
pulisher
Jul 27, 2025

Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Kilgore News Herald

Jul 27, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com

Jul 25, 2025
pulisher
Jul 25, 2025

Decoding Iovance Biotherapeutics: A TIL Breakout or Premature Optimism? - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics Soars 13.37% on FDA Approval, Buy Rating - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Iovance Biotherapeutics Inc. stockUnprecedented market success - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

About Us - FinancialContent

Jul 24, 2025
pulisher
Jul 24, 2025

Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com

Jul 24, 2025

Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$75.59
price up icon 0.93%
$37.11
price up icon 0.84%
$108.69
price up icon 1.31%
$27.07
price up icon 2.65%
$107.34
price down icon 0.15%
biotechnology ONC
$299.01
price down icon 0.70%
Kapitalisierung:     |  Volumen (24h):